Analysts Anticipate Immune Design Corp. (IMDZ) Will Announce Quarterly Sales of $620,000.00
Brokerages predict that Immune Design Corp. (NASDAQ:IMDZ) will report sales of $620,000.00 for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Immune Design Corp.’s earnings, with the lowest sales estimate coming in at $400,000.00 and the highest estimate coming in at $840,000.00. Immune Design Corp. reported sales of $8.21 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 92.4%. The business is scheduled to issue its next earnings report on Wednesday, November 8th.
According to Zacks, analysts expect that Immune Design Corp. will report full year sales of $620,000.00 for the current fiscal year, with estimates ranging from $7.00 million to $11.00 million. For the next fiscal year, analysts anticipate that the firm will report sales of $16.54 million per share, with estimates ranging from $15.08 million to $18.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Immune Design Corp..
Immune Design Corp. (NASDAQ:IMDZ) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.11. The business had revenue of $0.73 million for the quarter, compared to analyst estimates of $1.50 million. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%.
Several equities research analysts have weighed in on the stock. BidaskClub cut shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. Royal Bank Of Canada assumed coverage on shares of Immune Design Corp. in a research report on Thursday. They set an “outperform” rating and a $20.00 price target for the company. ValuEngine raised shares of Immune Design Corp. from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Jefferies Group LLC reissued a “buy” rating and set a $18.00 price target on shares of Immune Design Corp. in a research report on Wednesday, June 28th. Finally, Cowen and Company reissued a “buy” rating on shares of Immune Design Corp. in a research report on Tuesday, June 6th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $16.33.
Immune Design Corp. (NASDAQ:IMDZ) traded up 0.54% during trading on Friday, reaching $9.35. 408,203 shares of the company traded hands. The firm’s market capitalization is $239.54 million. The firm’s 50 day moving average price is $9.69 and its 200 day moving average price is $7.90. Immune Design Corp. has a 12-month low of $4.50 and a 12-month high of $13.05.
In related news, Director Lewis W. Coleman bought 8,000 shares of the company’s stock in a transaction dated Friday, July 7th. The stock was purchased at an average cost of $9.27 per share, with a total value of $74,160.00. Following the transaction, the director now owns 40,000 shares in the company, valued at approximately $370,800. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Wayne Gombotz sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $11.43, for a total transaction of $114,300.00. Following the completion of the sale, the insider now directly owns 33,054 shares of the company’s stock, valued at $377,807.22. The disclosure for this sale can be found here. Over the last ninety days, insiders bought 30,000 shares of company stock valued at $272,760. Corporate insiders own 42.90% of the company’s stock.
Large investors have recently bought and sold shares of the company. State of Wisconsin Investment Board purchased a new stake in shares of Immune Design Corp. in the 2nd quarter worth about $117,000. Alliancebernstein L.P. purchased a new stake in shares of Immune Design Corp. in the 2nd quarter worth about $118,000. Bank of America Corp DE lifted its position in shares of Immune Design Corp. by 123.3% in the 1st quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 8,418 shares during the period. Virtu KCG Holdings LLC purchased a new stake in shares of Immune Design Corp. in the 2nd quarter worth about $153,000. Finally, Dimensional Fund Advisors LP lifted its position in shares of Immune Design Corp. by 9.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock worth $184,000 after purchasing an additional 1,600 shares during the period. 51.46% of the stock is owned by hedge funds and other institutional investors.
Immune Design Corp. Company Profile
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.